NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Post Q2 2024 Earnings of ($0.81) Per Share, HC Wainwright Forecasts

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) – Equities research analysts at HC Wainwright issued their Q2 2024 earnings estimates for NRx Pharmaceuticals in a research note issued to investors on Friday, August 2nd. HC Wainwright analyst V. Bernardino expects that the company will post earnings of ($0.81) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $19.00 target price on the stock. The consensus estimate for NRx Pharmaceuticals’ current full-year earnings is ($4.00) per share. HC Wainwright also issued estimates for NRx Pharmaceuticals’ Q3 2024 earnings at ($0.81) EPS and Q4 2024 earnings at ($0.86) EPS.

Separately, Ascendiant Capital Markets decreased their price target on shares of NRx Pharmaceuticals from $50.00 to $43.00 and set a “buy” rating for the company in a research report on Friday, June 7th.

NRx Pharmaceuticals Price Performance

Shares of NASDAQ:NRXP opened at $2.02 on Monday. The business has a 50-day moving average of $2.73 and a two-hundred day moving average of $18.83. The firm has a market capitalization of $21.62 million, a PE ratio of -0.64 and a beta of 1.26. NRx Pharmaceuticals has a 12 month low of $1.90 and a 12 month high of $7.33.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.74) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On NRx Pharmaceuticals

An institutional investor recently bought a new position in NRx Pharmaceuticals stock. AdvisorShares Investments LLC acquired a new position in NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 642,632 shares of the company’s stock, valued at approximately $296,000. AdvisorShares Investments LLC owned about 0.75% of NRx Pharmaceuticals at the end of the most recent reporting period. 4.27% of the stock is currently owned by institutional investors and hedge funds.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.